Atika Capital Management LLC Sage Therapeutics, Inc. Transaction History

Atika Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $5.4 Million - $7.31 Million	-38,500 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$157.85 - $183.09 $6.08 Million - $7.05 Million	38,500 New	38,500 $7.05 Million
Q2 2018 Aug 14, 2018	SELL	$140.36 - $175.76 $3.02 Million - $3.78 Million	-21,500 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $2.36 Million - $2.98 Million	15,500 Added 258.33%	21,500 $3.46 Million
Q4 2017 Feb 14, 2018	SELL	$60.72 - $167.34 $60,720 - $167,340	-1,000 Reduced 14.29%	6,000 $988,000
Q2 2017 Aug 14, 2017	BUY	N/A	7,000	7,000 $557,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Atika Capital Management LLC with notifications on news.